Trial · NCT01186783
Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine
NCT01186783, Phase 2, Unknown, Martin-Luther-Universität Halle-Wittenberg
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine. Trials, record NCT01186783. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01186783
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine
- NCT number
- NCT01186783
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Martin-Luther-Universität Halle-Wittenberg
- Conditions
- Multiple Organ Dysfunction Syndrome
- Interventions
- ivabradine
- First posted
- 2010-08-23
- Last updated
- 2010-09-08
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | mean heart rate | 4 days | percenage of patients with a reduction of the mean heart rate of at least 10 bpm 96 hours after the start of trial treatment |
| Secondary | morbidity | 4 days | group-differences and patient-related changes of morbidity measured by serial APACHE II score monitoring and Sequential Organ Failure Assessment (SOFA) score monitoring |
| Secondary | hemodynamic parameters | 4 days | group-differences and patient-related changes of hemodynamic parameters (cardiac index and cardiac power index) as a consequence of ivabradine treatment |
| Secondary | catecholamine dosage | 4 days | required catecholamine dosage measured by a vasopressor score |
| Secondary | microcirculation | 4 days | improvement of microcirculation as measured by sublingual capillary density and flow |
| Secondary | endothelial function | 4 days | improvement of endothelial function as measured by the "Reactive hyperemia peripheral arterial tonometry-index" |
| Secondary | mean heart rate | 48 hours | comparison of the mean heart rate between the treatment and control group after 24 and 48 hours |
| Secondary | mortality | 6 months | 28-day and 6 months mortality |
| Secondary | cardiac autonomic dysfunction | 4 days | impact on cardiac autonomic dysfunction (heart rate variability quantified by time domain measurements (standard deviation of normal to normal interval (SDNN)) and frequency domain measurements (very low frequency (VLF)-, high frequency (HF)- and low frequency (LF)-power) as well as minimum, maximum, day and night heart rate) |
| Secondary | number of participants with adverse events as a measure of safety and tolerability | 6 months |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers36
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01186783
GET https://conductscience.org/api/trials/v1/NCT01186783/papers?page=2